scholarly journals P458Changes of pulmonary vasoactive factors and its relation with pulmonary arterial hypertension in patients with high altitude pulmonary edema

2014 ◽  
Vol 103 (suppl 1) ◽  
pp. S84.2-S84
Author(s):  
Q Zhou
Pneumologie ◽  
2018 ◽  
Vol 72 (S 01) ◽  
pp. S64-S64
Author(s):  
C Eichstaedt ◽  
H Mairbäurl ◽  
J Song ◽  
N Benjamin ◽  
C Fischer ◽  
...  

Author(s):  
Christina Eichstaedt ◽  
Heimo Mairbäurl ◽  
Jie Song ◽  
Nicola Benjamin ◽  
Christine Fischer ◽  
...  

2011 ◽  
Vol 179 (2-3) ◽  
pp. 294-299 ◽  
Author(s):  
Rémi Mounier ◽  
Aimé Amonchot ◽  
Nicolas Caillot ◽  
Cécile Gladine ◽  
Bernard Citron ◽  
...  

2017 ◽  
Vol 2017 (2) ◽  
Author(s):  
Adrian H Chester ◽  
Magdi H Yacoub ◽  
Salvador Moncada

The pathogenesis of pulmonary arterial hypertension remains undefined. Changes in the expression and effects mediated by a number of vasoactive factors have been implicated to play a role in the onset and progression of the disease. The source of many of these mediators, such as nitric oxide (NO), prostacyclin and endothelin-1 (ET-1), is the pulmonary endothelium. This article focus in the role of nitric oxide in PAH, reviewing the evidence for its involvement in regulation of pulmonary a vascular tone under physiological conditions, the mechanisms by which it can contribute to the pathological changes seen in PAH and strategies for the use of NO as a therapy for treatment of the disease. 


2015 ◽  
Vol 118 (3) ◽  
pp. 292-298 ◽  
Author(s):  
Sandro Altamura ◽  
Peter Bärtsch ◽  
Christoph Dehnert ◽  
Marco Maggiorini ◽  
Günter Weiss ◽  
...  

Low iron availability enhances hypoxic pulmonary vasoconstriction (HPV). Considering that reduced serum iron is caused by increased erythropoiesis, insufficient reabsorption, or elevated hepcidin levels, one might speculate that exaggerated HPV in high-altitude pulmonary edema (HAPE) is related to low serum iron. To test this notion we measured serum iron and hepcidin in blood samples obtained in previously published studies at low altitude and during 2 days at 4,559 m (HA1, HA2) from controls, individuals with HAPE, and HAPE-susceptible individuals where prophylactic dexamethasone and tadalafil prevented HAPE. As reported, at 4,559 m pulmonary arterial pressure was increased in healthy volunteers but reached higher levels in HAPE. Serum iron levels were reduced in all groups at HA2. Hepcidin levels were reduced in all groups at HA1 and HA2 except in HAPE, where hepcidin was decreased at HA1 but unexpectedly high at HA2. Elevated hepcidin in HAPE correlated with increased IL-6 at HA2, suggesting that an inflammatory response related to HAPE contributes to increased hepcidin. Likewise, platelet-derived growth factor, a regulator of hepcidin, was increased at HA1 and HA2 in controls but not in HAPE, suggesting that hypoxia-controlled factors that regulate serum iron are inappropriately expressed in HAPE. In summary, we found that HAPE is associated with inappropriate expression of hepcidin without inducing expected changes in serum iron within 2 days at HA, likely due to too short time. Although hepcidin expression is uncoupled from serum iron availability and hypoxia in individuals developing HAPE, our findings indicate that serum iron is not related with exaggerated HPV.


2020 ◽  
Vol 10 (4) ◽  
pp. 204589402096434
Author(s):  
Shoaib Fakhri ◽  
Kelly Hannon ◽  
Kelly Moulden ◽  
Ryan Peterson ◽  
Peter Hountras ◽  
...  

Background WHO Group 1 pulmonary arterial hypertension is a progressive and potentially fatal disease. Individuals living at higher altitude are exposed to lower barometric pressure and hypobaric hypoxemia. This may result in pulmonary vasoconstriction and contribute to disease progression. We sought to examine the relationship between living at moderately high altitude and pulmonary arterial hypertension characteristics. Methods Forty-two US centers participating in the Pulmonary Hypertension Association Registry enrolled patients who met the definition of WHO Group 1 pulmonary arterial hypertension. We utilized baseline data and patient questionnaire responses. Patients were divided into two groups: moderately high altitude residence (home ≥4000 ft) and low altitude residence (home <4000 ft) based on zip-code. Clinical characteristics, hemodynamic data, patient demographics, and patient reported quality of life metrics were compared. Results Controlling for potential confounders (age, sex at birth, body mass index, supplemental oxygen use, race, 100-day cigarette use, alcohol use, and pulmonary arterial hypertension medication use), subjects residing at moderately high altitude had a 6-min walk distance 32 m greater than those at low altitude, despite having a pulmonary vascular resistance that was 2.2 Wood units higher. Additionally, those residing at moderately high altitude had 3.7 times greater odds of using supplemental oxygen. Conclusion Patients with pulmonary arterial hypertension who live at moderately high altitude have a higher pulmonary vascular resistance and are more likely to need supplemental oxygen. Despite these findings, moderately high altitude Pulmonary Hypertension Association Registry patients have better functional tolerance as measured by 6-min walk distance. It is possible that a “high-altitude phenotype” of pulmonary arterial hypertension may exist. These findings warrant further study.


CHEST Journal ◽  
2019 ◽  
Vol 156 (1) ◽  
pp. 45-52 ◽  
Author(s):  
Nauman A. Khan ◽  
Rizwan A. Khan ◽  
Adriano R. Tonelli ◽  
Kristin B. Highland ◽  
Neal F. Chaisson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document